For the quarter ending 2025-09-30, DNA made $38,837,000 in revenue. -$80,412,000 in net income. Net profit margin of -207.05%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 38,837,000 | 49,604,000 | 48,318,000 | 40,895,500 |
| Cost of biosecurity revenue-Biosecurity | 8,177,000 | - | - | - |
| Cost of biosecurity revenue-Other Revenue | 4,625,000 | - | - | - |
| Research and development | 69,353,000 | 53,370,000 | 70,923,000 | 96,613,333.333 |
| General and administrative | 44,954,000 | 43,279,000 | 49,043,000 | 59,958,666.667 |
| Cost of biosecurity revenue | - | - | 12,047,000 | 9,637,250 |
| Cost of biosecurity revenue-Product And Service Other | - | 5,380,000 | - | - |
| Goodwill impairment | 0 | 0 | - | 9,447,250 |
| Cost of biosecurity revenue-Biosecurity Segment | - | 8,583,000 | - | - |
| Restructuring charges | 1,745,000 | 3,674,000 | 5,273,000 | 6,043,000 |
| Total operating expenses | 128,854,000 | 115,145,000 | 137,286,000 | 181,699,500 |
| Loss from operations | -90,017,000 | -65,541,000 | -88,968,000 | -140,804,000 |
| Interest income, net | 5,742,000 | 6,083,000 | 6,081,000 | - |
| Gain (loss) on investments | 3,684,000 | -229,000 | -3,693,000 | -7,544,500 |
| Loss on deconsolidation of subsidiary | 0 | - | - | - |
| Change in fair value of warrant liabilities | 0 | 0 | - | -470,000 |
| Interest income | - | - | - | 9,653,000 |
| (loss) gain on deconsolidation of subsidiaries | - | - | - | 0 |
| Interest expense | - | - | - | 19,482,000 |
| Other income (expense), net | -163,000 | -896,000 | -4,289,000 | 1,532,000 |
| Total other income (expense) | 9,263,000 | 4,958,000 | -1,901,000 | 3,934,500 |
| Loss before income taxes | -80,754,000 | -60,583,000 | -90,869,000 | -136,869,500 |
| Income tax (benefit) expense | 1,000 | -283,000 | 88,000 | -147,000 |
| Net loss | - | -60,300,000 | -90,957,000 | -136,757,250 |
| Net loss | -80,755,000 | - | - | -136,722,500 |
| Foreign currency translation adjustment | 27,000 | 2,586,000 | - | - |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | 0 | - | - | - |
| Debt securities, available-for-sale, unrealized gain (loss) | - | -83,000 | - | - |
| Unrealized gains (loss) on available-for-sale securities | 316,000 | - | - | - |
| Total other comprehensive (loss) income | 343,000 | 2,503,000 | - | - |
| Comprehensive loss | -80,412,000 | -57,797,000 | - | - |
| Basic (in shares) | 55,633,718 | 54,858,982 | 54,241,619 | -1,027,573,180.5 |
| Diluted (in shares) | 55,633,718 | 54,858,982 | 54,241,619 | -1,027,687,680.5 |
| Net loss per share, basic (in dollars per share) | -1.45 | -1.1 | -1.68 | -4.675 |
| Net loss per share, diluted (in dollars per share) | -1.45 | -1.1 | -1.68 | -4.675 |
Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. (DNA)